David J. Sas

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton et al. · New England Journal of Medicine · 2021 · 495 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +10

Increasing Incidence of Kidney Stones in Children Evaluated in the Emergency Department

David J. Sas, Thomas C. Hulsey, Ibrahim F. Shatat et al. · The Journal of Pediatrics · 2010 · 270 citations

Medicine, Nephrology, Pediatrics +15

Annual Incidence of Nephrolithiasis among Children and Adults in South Carolina from 1997 to 2012

Gregory E. Tasian, Michelle Ross, Lihai Song et al. · Clinical Journal of the American Society of Nephrology · 2016 · 260 citations

Public Health, Nephrology, Pediatrics +15

Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children

David J. Sas, Daniella Magen, Wesley Hayes et al. · Genetics in Medicine · 2021 · 74 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +15

Effect of claudins 6 and 9 on paracellular permeability in MDCK II cells

David J. Sas, Mingchang Hu, Orson W. Moe et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 2008 · 55 citations · Full text

Life Sciences, Cell Biology, Physiology +17